The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hevolution Global Healthspan Summit 29th-30th November 2023
Igniting a Healthy Evolution
Unveiling the Global Healthspan Summit - Together We Thrive! Brought to you by the visionary Hevolution Foundation, this remarkable gathering of thought leaders promises to revolutionize how we view aging and healthspan science.
Where Visionaries Unite
Join us as we assemble the brightest minds, forward-thinking entrepreneurs, and influential stakeholders from across the globe! Scientists & Research Institutions, Innovators & entrepreneurs, investors, corporate leaders, international organizations & non-profits, and dignitaries will come together to facilitate action-based conversations and drive impact around catalyzing international collaboration in the emerging field of healthspan science.
Empowering Action Through Collaboration
No more passive discussions - it’s time for an honest, transformative change! Our Summit is all about action-driven conversations that will fuel groundbreaking research, cutting-edge entrepreneurship, and intelligent investments. Together, we’ll catalyze a global movement that will reshape the future of healthspan science.
A CRITICAL JUNCTION FOR CHANGE
We believe now is the decisive moment for decision-makers, investors, visionaries, governments, and researchers to unite. Let’s understand aging processes and elevate the discussion by exploring how to enhance the intersectional factors that promote healthy aging.
UNLEASHING THE POWER OF ACTION
The Global Healthspan Summit is more than just a platform - it’s a catalyst for change! Across two pivotal days, leading minds will convene to discuss the latest insights, facilitating networking and knowledge exchange like never before.
htTps://hevolution.com/en/ghs
Dr Khan added: “We have also evaluated more than 150 companies around the world. We’ve already built a database with the companies that are active in the aging space globally. And we’ve received applications and letters of intent from scientists from around the world. Over 500 scientists have applied one way or another to collaborate with the Fund and get funding from us in this field.”
Let's hope Genflow are on the radar of Hevolution and their $1 billion annual investment into promising early stage longevity biotechs.
Genflow's new collaboration with
Magnaetus Therapeutics have just been awarded $50,000 from the healthspan challenge and now go forward to the next stage of the challenge, where $1 million will be awarded in January for the most promising longevity therapies, followed by a grand prize of $5m in June. Gla ;-)
htTps://healthylongevitychallenge.org/winners/developing-therapeutic-agents-reverse-ageing-and-metabolic-decline/
hTtps://healthylongevitychallenge.org/event/2023-healthy-longevity-global-innovator-summit/
Four years ago, by royal decree, Saudi Arabia’s Crown Prince Mohammed bin Salman pledged a vast financial investment - over a billion dollars a year - into research that would extend the healthy human lifespan, which led to the birth of the Kingdom’s Hevolution Foundation.
The Foundation - a global fund that aims to find and invest in innovative ways to “decelerate” the aging process and extend the number of years people live in good health - is heavily invested in academic research and biotech startups that promote longevity by slowing aging and combating age-related diseases.
.....
“We are an organization that’s helping all humanity,” she said, adding that the initiative aims to be the first non-profit to pursue age-related therapeutic breakthroughs. It is committed to funding global scientific discovery, and investing in private companies and entrepreneurs dedicated to advancing aging science.
“Hevolution wants to become a convener and to become a catalyst in the field and bridge the gap in the funding in terms of investment and in science, and the Hevolution Foundation has done multiple activities in the past year to ensure that we develop this convening and catalyst platform to move the healthspan science forward for the benefit of all of humanity.”
Dr al-Saud said therapeutics that extend a healthy human lifespan will redefine healthcare in the 21st century.
As of 2023, the non-profit organization has expanded outside the Kingdom’s borders – which houses its Riyadh headquarters – into its first international hub in Boston, Massachusetts. The US office makes it the country’s biggest hub for life sciences. It is eying up a further global hub in the United Kingdom by the end of the year and has plans for an Asia hub.
It has also, in the past 18 months, pledged $200 million for research into anti-aging, longevity biotech and healthy lifespan, a planned investment in two biotech companies, evaluated more than 150 companies across the globe as it eyes funding opportunities, is whittling down more than 500 grant applications from scientists around the world, has published the GCC’s first roadmap in healthy human lifespan, and is gearing to host the Kingdom’s first Global Healthspan Summit in November.
htTps://www.google.com/amp/s/english.alarabiya.net/amp/infocus/2023/09/28/Saudi-Princess-Inside-the-Kingdom-s-billion-dollar-project-to-extend-human-lifespan
hTtps://hevolution.com/en/ghs
Only a matter of time before Genflow receives similar attention from like minded investors .Gla :-)
LifeSpan Vision Ventures Makes 7th Investment in Pursuit of Longevity Mission
LifeSpan Vision Ventures
13 Oct, 2023,
"We are excited to unveil our seventh investment as we continue to forge ahead in the field of longevity," said Harry Robb, Analyst at LifeSpan Vision Ventures. "Our dedication to extending healthspan and enabling a longer, healthier, more fulfilling life for all remains at the core of our mission. We believe that the companies we invest in will play a pivotal role in driving forward the next wave of biotech solutions that promise a brighter future."
htTps://www.prnewswire.com/news-releases/lifespan-vision-ventures-makes-7th-investment-in-pursuit-of-longevity-mission-301956596.html
Tower's SA acerage straddles TotalEnergies two mega gas discoveries which are expected to transform SA's energy security . Gla :-)
S.Africa's gas master plan ready, official says
Reuters
October 10, 20231:22 PM
TotalEnergies SE
CAPE TOWN, Oct 10 (Reuters) - South Africa's master plan to develop its gas market is finally ready after repeated delays as it aims to reduce its carbon emissions and avoid chronic power outages that have plagued Africa's most developed economy for years.
The master plan will go to the cabinet before public release, a senior official at the department of mineral resources and energy (DMRE) said on Tuesday.
"It is done, it is going through the internal processes to go to cabinet for public comment", Jacob Mbele, the chief director at the DMRE told journalists.
South Africa wants to diversify its energy mix away from ageing coal-fired power plants prone to breakdowns and help reduce harmful emissions from the continent's top polluter. The country estimates it has gas resources of around 60 trillion cubic feet (tcf) offshore and a further 200 tcf onshore.
The failure to come up with a master plan, first raised almost a decade ago, has added to regulatory uncertainty in South Africa, where French energy company TotalEnergies (TTEF.PA) was looking to develop two large offshore gas finds.
Another DMRE official said last month the new gas master plan was designed to balance the demand and supply of natural gas until 2050, modelled on data gleaned and verified by the industry.
The gas master plan uses three scenarios - low, medium and high - and showed that gas-to-power projects will initially dominate gas uptake in South Africa as the country looks to re-purpose decommissioned coal-fired plants to run on gas.
The plan also considers that South Africa, which gets the bulk of its gas from petrochemical major Sasol's (SOLJ.J) fields in Mozambique, will face an imminent gas shortage from 2026 as these fields start running dry.
The gas master plan is expected to be made public before the end of December.
0 0 0
So in essence, VitaDAO, a longevity biotech company funded by Pfizer, is in turn funding Matrix Biosciences who have appointed Vera Gorbunova as their lead scientist, who is Genflow's number one lead collaborator from University of Rochester and her R&D into Sirt6, and VitaDAO are also funding Magnateus Biotech, who have just confirmed they're in collaboration with Genflow on their longevity R&D....All bodes well for Genflow imho, especially given how advanced they're are in progress towards their two human clinical trials for Nash & Werner Syndrome....Exciting times and very encouraging with Pfizer in the background. Gla holders:-)
Pfizer connection and association.....Very interesting. Gla holders ;-)
Pfizer-backed VitaDAO spins out biotech company
VitaDAO, which funds longevity research, announced the $300,000 financing of a biotechnology company, the DAO’s first such investment
htTtps://blockworks.co/news/vitadao-pfizer-biotech-arm
HTtps://gov.vitadao.com/t/vdp-117-magnaetus-therapeutics/1417
Global online DAO approves launch and financing of MatrixBio to optimal drug candidates for age-related diseases.
VitaDAO, the global online community driving early-stage longevity research through innovative funding collaborations has announced the launch of its very first biotech company – Matrix Biosciences. This significant milestone comes from a community-wide vote and approval in favor of a collaboration with Vera Gorbunova, PhD, Co-Chair of the University of Rochester’s Aging Research Center.
htTps://longevity.technology/news/vitadao-community-launches-its-first-biotech-company/
Material news!!!??? Gla ;-)
2023 Healthy Longevity Global Innovator Summit
09/26/2023 8:00am
The evolving role of generative artificial intelligence in healthcare was front and center at the annual Healthy Longevity Global Innovator Summit, with experts expounding on its potential to help people live longer, healthier lives. Delivering the conference keynote was Peter Lee, Microsoft Corporate Vice President of Research and Incubations, who had a personal link to the topic of AI and medicine.
.........................
Developing therapeutic agents reverse ageing and metabolic decline
Cary Depel; Paul Baldock; Guy Barry | Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences
Competition Sponsor: US National Academy of Medicine
Awardee Year: 2023
Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.
To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.
Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.
htTps://healthylongevitychallenge.org/winners/developing-therapeutic-agents-reverse-ageing-and-metabolic-decline/
hTtps://healthylongevitychallenge.org/event/2023-healthy-longevity-global-innovator-summit/
Fully funded until March 2025 and so amazed to see this fall to sub 2p, although presents a great opportunity to accumulate cheap shares with undoubted multi-bag potential in the coming weeks and months as good news is delivered. Gla holders..:-)
My £3k top up at 1.55p is showing as a sell. Gla :-)
Plenty of material news to get the sp heading North expected in the coming weeks.
Eric confirmed in his recent interview they're in negotiations for two new non-dilutive funding grants expected to provide funding for an additional 3 years for 80% of their R&D, news if which could drop at anytime, followed by the Final Reports from their 4 academic collaborations which should be very well received.
Gla holders, the current bargain low offers tremendous UPside as progress is made and every chance of a major investor or JV partner in the Pipeline, given the huge promise of Sirt6's potency and importance in longevity, healthspan and multiple disease targets. ;-)
28/9/23
The Company continues to maintain a secure financial position and has sufficient cash reserves until March 2025. This is inclusive of grant funding which has been approved at the time of reporting and is due to be received in the coming months. The Company continues to seek further non-dilutive research grants which management will use to expedite specific phases of planned research and development.
......
The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.
These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.
28/9/23 Half Year Report
-- The Group has expanded its intellectual property portfolio through a provisional patent application focussing on the ability to edit its SIRT6 gene. If granted, the patent will represent a significant breakthrough in the field of gene editing, with potential implications for longevity and other forms of gene therapy.
.......
1.20230018934
METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS
US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688
Applicant GENFLOW BIOSCIENCES SRL
Inventor Eric LEIRE
Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.
Perenco’s recent success in a marginal field in shallow water, has many similarities to Njom-3. Gla ;-)
Cameroon
June 29, 2023
Perenco has completed the South Kole Marine oil development 50 km offshore Cameroon.
PARIS, France — Perenco has completed the South Kole Marine oil development 50 km offshore Cameroon.
The marginal field, discovered by a previous operator in the 1980s, is in 30 m to 50 m water depth.
Following an eight-month program—which according to the company involved innovations in terms of well architecture, pipelay and the type of platforms installed—production is currently above 3,800 bbl/d.
Earlier this month, Perenco signed a new 20-year production sharing contract with Société Nationale des Hydrocarbures for continued development of the Rio del Rey Basin, also offshore Cameroon.
Ps Dissoni is North of Njom-3....:-)
The area has been explored by Pecten (Shell) and ELF (now Total) since the 1960s with several discoveries made within an earlier licence. As a result, the current Thali Block includes the Total’s Njonji-1 discovery well drilled in 2008 which encountered 35° API oil in several shallow stacked Pliocene sands. The Njonji-2, appraisal well confirmed the discovery in 2010, but was deemed uncommercial at that time before any testing, leading to Total’s strategic exit and sale of its entire Cameroon portfolio to Perenco in 2011. Perenco put the Dissoni field into production, immediately to the north of the current Thali Block, before relinquishing the rest of the licence. Tower then applied for, and were awarded the Thali Block in 2015. Since then, they have reprocessed the 3D seismic originally acquired in 1991 over part of the Block, including over the Njonji discovery. This new data has provided a more accurate definition of the Njonij structure, its closures and their commercial potential. Tower is now seeking a strategic partner to join them in funding the planned Njonji-3 appraisal well to flow test the oil in the Pliocene sands, followed by a rapid development. The Njonji-3 well is drill-ready. All long-lead items have been purchased, the site survey is completed and rig contract under negotiation.
An independent CPR completed by Oilfield International in October 2018 has confirmed an initial two-phase development could exploit the ‘mean’ 18 MMbbls contingent recoverable resources (and upside of 34+ MMbls rec) from the three primary Pliocene reservoir sands in the northern Njonji closure above 1,100 metres. Follow-on drilling could then exploit a gross ‘mean’ prospective resources of 20 MMbbls in the southern closure, which has an upside potential of 74+ MMbbls rec.
The economics show a four well ‘stand-alone’ development of just the contingent Northern Njonji resource potential is commercial. This could produce 8,000 bopd, with the proximity to local infrastructure providing rapid cash flow with recovery of exploration costs under the PSC from potential annual cash flows of >$100 million and an EMV10 of US$118 million. An additional EMV10 of US$82 million is calculated for the development of the prospective Southern Njonji resource potential. Substantial 100+ MMboe potential upside remains undrilled in the Dissoni South and Idenao East analogue prospects in the Block, immediately south of Perenco’s Dissoni field.
The undrilled deep exploration play potential in the Thali PSC offers equally large resource upside already proven on trend in the deeper Rio del Rey Basin. In addition to the Alba and Zafiro fields, the Isongo fields lie on trend to the south east of the Thali Block.
Perenco’s Dissoni oil producing block is south of Thali, and it was Total who made the discovery in 2008, but deemed the volume weren't big enough for a Major and so Total relinquished the block and Perenco took ownership. Perenco has never drilled Thali and they in turn relinquished the block around 2015, as they were so busy with the rest of their numerous prospects in the Rio Del Rey basin, and that’s when Tower took ownership....35m plus barrel potential is peanuts for Total who are only interested in mega discoveries similar to their current success offshore Namibia, but 35m barrels for Tower would be well and truly transformational. Gl :-)
Consensus recommendation to immediately expand research on extending healthy human lifespans.
The Longevity Escape Velocity Foundation (LEVF) has welcomed the publication today of the Dublin Longevity Declaration. This Declaration calls on governments, funding agencies and the public to intensify their support for the promising interventional ideas that exist to fight age-related suffering and disease, and for the generation and exploration of further ways to extend healthy lifespan.
hTtps://longevity.technology/news/scientific-leaders-issue-global-dublin-longevity-declaration/amp/
Any large buy would take time to fill, especially a huge one for 117,500,000, and then gets reported after close when the broker balances his book for all trades that day, sometimes it and take several days before it's reported depending on liquidity. Gl ;-)